SHARE THIS ARTICLE
Xolair
Xolair Injection Uses: Essential Clinical Overview
Apr 17, 2025
Allergies affect millions worldwide, with over 100 million people in the U.S. experiencing allergic conditions annually. These reactions occur when the immune system misidentifies harmless substances as threats, triggering symptoms from mild discomfort to life-threatening anaphylaxis. While antihistamines and corticosteroids provide relief, many patients with severe allergies require targeted treatments to manage persistent symptoms.
Xolair (omalizumab) is a monoclonal antibody designed to help patients with severe allergic asthma and chronic spontaneous urticaria. By blocking immunoglobulin E (IgE), Xolair minimizes allergic reactions, reducing symptoms and flare-ups. This mechanism offers a more precise approach than traditional allergy medications, providing long-term benefits for patients with uncontrolled allergic conditions.
This article will explore Xolair’s essential clinical applications, effectiveness, safety profile, and key research supporting its role in allergy management.
Key Takeaways
- Xolair is FDA-approved for moderate to severe allergic asthma not controlled by inhaled corticosteroids.
- It is also approved for chronic spontaneous urticaria (CSU) in patients who don’t respond to antihistamines.
- Xolair targets and blocks IgE, a key antibody in allergic and inflammatory responses.
- Off-label uses include chronic rhinosinusitis with nasal polyps, food allergies, and allergic bronchopulmonary aspergillosis.
- Patient selection is based on IgE levels, body weight, and symptom severity across approved indications.
- Clinical studies show significant reductions in asthma exacerbations and improved quality of life in urticaria patients.
About: Trusted by over 2,000+ global clients since 2014, Maylips has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Maylips offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world. If you’re looking to buy Xolair online, contact our sales team for guidance.
Approved Indications for Xolair Injection
Xolair (omalizumab) is FDA-approved for three primary indications. These conditions involve IgE-mediated immune responses, where Xolair is used as an add-on therapy when standard treatments are insufficient. The approved indications are:
- Allergic Asthma: Patients aged 6 years and older with moderate to severe persistent asthma. Must have a positive skin test or in vitro reactivity to a perennial aeroallergen, and symptoms not controlled by inhaled corticosteroids.
- Chronic Spontaneous Urticaria (CSU): For patients 12 years and older with hives lasting more than 6 weeks despite H1-antihistamine therapy.
- Nasal Polyps: Approved for adults with nasal polyps not adequately controlled by intranasal corticosteroids.
These indications reflect Xolair’s role in managing difficult-to-treat allergic conditions where IgE plays a key role in the disease process.
Mechanism of Action of Xolair Injection
Xolair targets immunoglobulin E (IgE), a central component in allergic reactions. It binds specifically to free IgE in the bloodstream, preventing it from attaching to receptors on mast cells and basophils. This blocks the allergic cascade and reduces the inflammatory response of allergic diseases. Key steps in its action include:
- Binding to the Cε3 domain of IgE
- Reducing surface-bound IgE receptors on immune cells
- Inhibiting mast cell degranulation and histamine release
- Decreasing cytokine production and inflammatory signaling
The overall effect is diminished allergic inflammation, symptom severity, and hypersensitivity to allergens in approved conditions.
Emerging and Off-Label Uses of Xolair Injection
Researchers have expanded the use of Xolair beyond its FDA-approved indications to various off-label and investigational settings. Clinicians may consider these uses in practice based on supporting evidence and individual patient needs, even though the FDA has not officially approved them. Common off-label and emerging uses include:
- Food Allergies: Particularly peanut allergy, in combination with oral immunotherapy, to reduce reactions.
- Allergic Rhinitis: As an adjunct to reduce symptoms in persistent allergic rhinitis.
- Chronic Rhinosinusitis with Nasal Polyps: Beyond FDA approval, studies show effectiveness in patients with severe congestion.
- Allergic Bronchopulmonary Aspergillosis (ABPA): Used in cystic fibrosis or asthma patients with hypersensitivity to fungal elements.
- Atopic Dermatitis: Under study to reduce flare-ups in moderate to severe eczema patients.
- Mast Cell Disorders: Used selectively in patients with systemic mastocytosis or idiopathic anaphylaxis.
These emerging uses highlight Xolair’s expanding role in managing complex allergic and immune conditions.
Patient Selection Criteria for Xolair Injection
Proper patient selection is essential for safe and effective treatment with Xolair. The selection process involves diagnostic testing, evaluation of symptoms, and assessment of prior treatment response to help minimize the risk of Xolair injection side effects.
Asthma
- Age 6 years and older
- IgE levels between 30 IU/mL and 700 IU/mL (up to 1500 IU/mL for ages 12+)
- Sensitivity to perennial allergens confirmed by testing
- Poor control with inhaled corticosteroids
Chronic Urticaria
- Age 12 years and older
- Diagnosis of spontaneous hives lasting more than 6 weeks
- Lack of adequate response to antihistamines
Nasal Polyps
- Adults 18 years and older
- Severe symptoms not relieved with intranasal corticosteroids
In all cases, body weight and serum IgE levels guide dosing. Patient history of hypersensitivity reactions must be reviewed, and anaphylaxis risk monitored during treatment.
Clinical Evidence Supporting Xolair Injection Uses
Doctors use Xolair (omalizumab), a monoclonal antibody, to treat severe allergic asthma, chronic spontaneous urticaria, and food allergies. Clinical trials have demonstrated its efficacy and safety. For chronic spontaneous urticaria, the ASTERIA I, ASTERIA II, and GLACIAL trials showed significant symptom reduction, with 53% of patients on the highest dose becoming hive-free.
In food allergy treatment, the Phase III OUtMATCH study revealed that 36% of patients treated with Xolair tolerated at least 2,000 mg of peanut protein and other allergens without reactions, compared to 19% in the oral immunotherapy group. These findings highlight Xolair’s potential to improve quality of life for patients with severe allergic conditions.
Conclusion
Doctors rely on Xolair injections as a critical therapeutic option to manage moderate to severe allergic conditions that conventional treatments fail to control. Targeting immunoglobulin E (IgE) effectively addresses a range of IgE-mediated disorders, including allergic asthma, chronic spontaneous urticaria, and nasal polyps.
Ongoing research continues to expand its clinical applications, highlighting its versatility and therapeutic potential. Clinicians achieve optimal outcomes by selecting appropriate patients and following evidence-based dosing protocols. Backed by substantial clinical data, Xolair remains a well-established and valuable agent in allergy and immunology practice.
FAQs
1. What is Xolair used for?
Xolair treats allergic asthma, chronic spontaneous urticaria, and nasal polyps in patients unresponsive to standard therapies.
2. How is Xolair administered?
Healthcare providers give Xolair as a subcutaneous injection, usually every 2 to 4 weeks, depending on the indication, body weight, and IgE levels.
3. How long does it take for Xolair to work?
Some patients may notice improvement in symptoms within a few weeks, but full effects may take 2 to 3 months.
4. What are the side effects of Xolair?
Common side effects include injection site reactions, headache, and fatigue. Rarely, anaphylaxis may occur and requires monitoring.
5. Can Xolair be self-injected at home?
Yes, Xolair is available in a prefilled syringe for self-administration after training by a healthcare provider.
6. Is Xolair safe during pregnancy?
Physicians should base the use of Xolair during pregnancy on a careful risk-benefit assessment, as human data are limited.
7. Do I need allergy testing before starting Xolair?
Yes, allergy testing is essential to confirm IgE sensitivity and guide appropriate dosing, particularly for asthma.
References
James J. Allergy Facts. Asthma & Allergy Foundation of America. Published April 2024. https://aafa.org/allergies/allergy-facts/
Cleveland Clinic. Allergies: Symptoms, Reaction, Treatment & Management. Cleveland Clinic. Published December 21, 2022. https://my.clevelandclinic.org/health/diseases/8610-allergies